AU2023205290A1 - Stable pharmaceutical composition of receptor agonist, and preparation method and application thereof - Google Patents

Stable pharmaceutical composition of receptor agonist, and preparation method and application thereof Download PDF

Info

Publication number
AU2023205290A1
AU2023205290A1 AU2023205290A AU2023205290A AU2023205290A1 AU 2023205290 A1 AU2023205290 A1 AU 2023205290A1 AU 2023205290 A AU2023205290 A AU 2023205290A AU 2023205290 A AU2023205290 A AU 2023205290A AU 2023205290 A1 AU2023205290 A1 AU 2023205290A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
buffer solution
active ingredient
composition according
regulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023205290A
Other languages
English (en)
Inventor
Li Dong
Yan Han
Haohua HAO
Yang Song
Jun Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of AU2023205290A1 publication Critical patent/AU2023205290A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2023205290A 2022-01-10 2023-01-09 Stable pharmaceutical composition of receptor agonist, and preparation method and application thereof Pending AU2023205290A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210021736.1 2022-01-10
CN202210021736 2022-01-10
PCT/CN2023/071277 WO2023131325A1 (zh) 2022-01-10 2023-01-09 一种稳定的受体激动剂的药物组合物、制备方法及其应用

Publications (1)

Publication Number Publication Date
AU2023205290A1 true AU2023205290A1 (en) 2024-07-11

Family

ID=87073306

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023205290A Pending AU2023205290A1 (en) 2022-01-10 2023-01-09 Stable pharmaceutical composition of receptor agonist, and preparation method and application thereof

Country Status (10)

Country Link
US (1) US20250170218A1 (https=)
EP (1) EP4464331A4 (https=)
JP (1) JP2024545887A (https=)
KR (1) KR20240135785A (https=)
CN (1) CN118488848A (https=)
AU (1) AU2023205290A1 (https=)
CA (1) CA3242599A1 (https=)
MX (1) MX2024007861A (https=)
TW (1) TW202333775A (https=)
WO (1) WO2023131325A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12102664B2 (en) * 2023-12-27 2024-10-01 Olfactive Biosolutions, LLC Compositions and methods for treating endocrine diseases and disorders
US12290550B1 (en) 2023-12-27 2025-05-06 Olfactive Ai, Inc. Compositions and methods for treating endocrine diseases and disorders
WO2025191149A1 (en) * 2024-03-15 2025-09-18 Krka, D.D., Novo Mesto Pharmaceutical composition comprising dual gip and glp-1 receptor agonist
WO2026007980A1 (zh) * 2024-07-03 2026-01-08 上海海雁医药科技有限公司 一种mor受体激动剂的液体组合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101366692A (zh) * 2007-08-15 2009-02-18 江苏豪森药业股份有限公司 一种稳定的艾塞那肽制剂
AU2013205144B2 (en) * 2008-06-17 2015-07-16 Indiana University Research And Technology Corporation GIP-based mixed agonists for treatment of metabolic disorders and obesity
CN102363633B (zh) * 2011-11-16 2013-11-20 天津拓飞生物科技有限公司 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
CN112351994B (zh) * 2019-04-11 2024-06-07 江苏豪森药业集团有限公司 一种多受体激动剂及其医药用途
CN111825758B (zh) * 2019-04-19 2024-11-22 上海翰森生物医药科技有限公司 Glp-1和gip共激动剂化合物
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
CN113383014B (zh) * 2019-11-15 2024-06-18 江苏豪森药业集团有限公司 双受体重激动剂化合物及其药物组合物
EP4110800A1 (en) * 2020-03-06 2023-01-04 Sanofi Peptides as selective gip receptor agonists
CN114349828B (zh) * 2020-11-27 2023-12-08 江苏师范大学 Glp-1/胰高血糖素受体双重激动剂及其应用

Also Published As

Publication number Publication date
CN118488848A (zh) 2024-08-13
EP4464331A4 (en) 2025-05-07
CA3242599A1 (en) 2023-07-13
US20250170218A1 (en) 2025-05-29
MX2024007861A (es) 2024-07-09
TW202333775A (zh) 2023-09-01
JP2024545887A (ja) 2024-12-13
WO2023131325A1 (zh) 2023-07-13
KR20240135785A (ko) 2024-09-12
EP4464331A1 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
AU2023205290A1 (en) Stable pharmaceutical composition of receptor agonist, and preparation method and application thereof
US7312196B2 (en) Formulations for amylin agonist peptides
US20120178675A1 (en) Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin
CN109640955B (zh) 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
JP2024545887A5 (https=)
JP2002511103A (ja) アミリン作動薬ペプチド用製剤
AU699113B2 (en) Method of administration of IGF-I
EP4591875A1 (en) Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
CN101095942B (zh) 一种包含稳定剂的Exendin-4注射剂药物配方
EP3811948B1 (en) Glycosides for use in preventing and treating diabetic complications
US12343383B2 (en) High concentration insulin formulation
CA3268560A1 (en) Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
CN114053217A (zh) 一种Exendin-4-Fc融合蛋白注射制剂及其制备方法
US20260014233A1 (en) Multi-dose pen of tirzepatide
WO2019129278A1 (zh) 培化西海马肽的药物组合物及其制备方法
WO2025190304A1 (zh) 包含glp-1和gip双受体激动剂的药物组合物及其用途
CN117693334A (zh) 培美曲塞二钠液体组合物、其制备方法及应用
EP4004138A1 (en) Dihydroergotamine mesylate formulations and pre-filled injectors for therapeutic delivery of the same
Sleightholm et al. Continuous subcutaneous insulin infusion does not provoke significant acute-phase response
HK40000201A (en) Pharmaceutical preparation containing polyethylene gylcol loxenatide and preparation method thereof
HK40000201B (zh) 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
CN1486696A (zh) 哌仑西平冻干粉针剂
US20160095904A1 (en) Stabilized liquid formulation